从人脂肪来源的间充质干细胞中纯化和表征细胞外囊泡
2024年5月3日
1.6K 次观看
该方案描述了所有程序，从培养人脂肪来源的间充质干细胞 （ADSC） 和收集上清液到使用超速离心提取细胞外囊泡 （EV）。
我们的研究重点是从人脂肪来源的间充质干细胞中制备和纯化细胞外囊泡。我们要解决的问题是如何规范这个过程，提高净化效率。目前，用于提取细胞外囊泡的技术很多，如超速离心、超滤、体积排阻色谱、聚合物沉淀、免疫亲和捕获、微流控技术等。
然而，不可否认，超速离心法被认为是黄金标准。未来，我们将专注于细胞外囊泡作为载体的应用，包括携带 MRNA、质粒和其他小分子并将它们转染到细胞中。
概述
本协议概述了从人类脂肪来源的间充质干细胞（ADSCs）中提取和纯化细胞外囊泡（EVs）的方法。重点是标准化提取过程以提高纯化效率。
关键研究组成部分
科学领域
- 神经科学
- 细胞生物学
- 干细胞研究
背景
- 细胞外囊泡在细胞间通信中起着关键作用。
- ADSCs是提取EV的一个有前景的来源。
- 存在多种EV提取技术，其中超速离心是金标准。
- 提高纯化效率对于未来应用至关重要。
研究目的
- 标准化从ADSCs提取EV的过程。
- 提高EV纯化的效率。
- 探索EV作为mRNA和质粒载体的应用。
使用的方法
- 人类脂肪来源的间充质干细胞的培养。
- 培养细胞的上清液的收集。
- 使用超速离心提取EV。
- 纯化效率的评估。
主要结果
- 开发了EV提取的标准化协议。
- 超速离心被证明对EV纯化有效。
- 确定了EV的未来应用，包括基因递送。
- 讨论了纯化效率的潜在改进。
结论
- 本研究为从ADSCs提取EV提供了一个框架。
- 标准化是提高纯化过程的关键。
- EV在基因递送的治疗应用中具有前景。
常见问题
什么是细胞外囊泡？
细胞外囊泡是细胞释放的膜结合颗粒，在细胞通信中起作用。
为什么使用ADSCs提取EV？
ADSCs是EV的易获得来源，并具有潜在的治疗应用。
EV提取的金标准是什么？
超速离心被认为是提取细胞外囊泡的金标准。
正在为EV探索哪些未来应用？
未来应用包括使用EV作为将mRNA和质粒递送到细胞中的载体。
如何提高EV的纯化效率？
标准化提取协议和探索新技术可以提高纯化效率。
Executive Industry Relevance
Standardized purification and characterization of extracellular vesicles (EVs) from human adipose-derived mesenchymal stem cells (ADSCs) addresses a critical need for reproducible, high-quality EV preparations in early-stage biopharma R&D. Reliable EV isolation underpins mechanistic studies, target validation, and the development of EV-based delivery systems. This workflow supports predictive confidence and translational continuity for regenerative and gene delivery applications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of paracrine signaling mechanisms relevant to tissue regeneration.
- Supports functional validation of EV-mediated intercellular communication pathways.
- Facilitates biological de-risking by providing standardized EV preparations for hypothesis testing.
Screening & Assay Development
- Delivers reproducible EV samples for downstream quantitative assays and biomarker analysis.
- Supports assay standardization by minimizing batch-to-batch variability in EV isolation.
- Enables reliable evaluation of EV cargo and functional properties in screening platforms.
Translational & Preclinical Research
- Provides disease-relevant EVs for preclinical model studies in regenerative medicine.
- Aligns with translational biomarker strategies by enabling consistent EV characterization.
- Supports risk-adjusted advancement of EV-based therapeutic vectors.
Pipeline & Workflow Integration
This EV purification protocol integrates into the discovery-to-preclinical continuum, supporting both mechanistic studies and translational research on EV-based delivery systems.
- Discovery Biology: Standardized EV isolation enables robust hypothesis testing of paracrine and regenerative mechanisms.
- Screening: Quantitative EV characterization (size, morphology, marker expression) supports assay readiness and reproducibility.
- Analytics: Nanoparticle tracking and Western blot outputs provide quantitative and qualitative EV metrics for cross-condition comparison.
- Translational Research: Consistent EV preparations facilitate preclinical evaluation of regenerative and gene delivery applications.
- Enterprise Reuse: The protocol establishes a reusable platform for EV isolation across diverse R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in EV-mediated mechanisms and target validation.
- Operational Value: Enhances reproducibility and standardization of EV isolation workflows.
- Strategic Value: Supports informed go/no-go decisions for EV-based therapeutic development.
- Portfolio Impact: Enables risk-adjusted prioritization of EV-related assets and translational projects.
Implementation Considerations
- Requires expertise in cell culture, ultracentrifugation, and EV analytics (TEM, nanoparticle tracking, Western blot).
- Demands access to high-speed ultracentrifugation and analytical instrumentation.
- Necessitates cross-team standardization to ensure reproducibility and comparability of EV preparations.
- Adaptation may be needed for different cell sources or EV subtypes.
- Limitations include potential EV aggregation and low recovery rates inherent to ultracentrifugation.
Biopharma FAQs
Why does null hypothesis testing matter for EV target validation?
Null hypothesis testing using standardized ADSC-derived EVs enables rigorous evaluation of their functional role in paracrine signaling and tissue regeneration, reducing mechanistic ambiguity in early discovery. This supports confident target validation and informs downstream R&D decisions.
How does independent variable isolation fit the EV purification workflow?
Isolating variables such as cell passage, culture conditions, and ultracentrifugation parameters ensures that observed EV characteristics and functions are attributable to the intended experimental factors, supporting reproducibility and mechanistic clarity in the discovery pipeline.
What do quantitative EV size and marker measurements enable?
Quantitative measurements from nanoparticle tracking and Western blot analysis provide objective criteria for EV quality and identity, enabling reliable comparison across batches and supporting assay development and translational research.
Why are replication requirements critical for cross-functional EV studies?
Replication of EV isolation and characterization steps ensures that findings are robust and transferable across teams, facilitating cross-functional collaboration and reducing risk in portfolio advancement.
What statistical analysis capabilities are needed before EV workflow implementation?
Statistical analysis of EV size distribution, yield, and marker expression is essential to validate protocol consistency, assess batch variability, and establish quality thresholds prior to broader R&D deployment.
